Home / Market News / $DARE
benzinga Corporate Catalyst Impact 65/100 ● neutral

Daré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11

Oct 8, 2026, 1:21 PM UTC · Primary ticker $DARE

Daré Bioscience announced it will present positive Phase 1 clinical data for its Sildenafil Cream, 3.6% investigational product, at the SMSNA meeting. The data shows significantly lower systemic exposure compared to oral sildenafil with mild adverse events, supporting further development for female sexual arousal disorder (FSAD). This is a positive development for the company's pipeline, potentially de-risking the asset and attracting investor interest.

Daré Bioscience is presenting positive Phase 1 clinical data for its Sildenafil Cream, 3.6% at a medical conference. The key finding is that the topical cream delivers sildenafil with substantially lower systemic exposure (187-fold lower mean maximum plasma concentration) and a favorable safety profile compared to oral sildenafil. This is significant because it supports the rationale for topical delivery and de-risks the product's development, particularly for its intended use in women with female sexual arousal disorder (FSAD), a condition with no FDA-approved pharmacological treatments. For traders, this news could lead to short-term positive sentiment and increased interest in DARE, as it validates a key pipeline asset and potentially accelerates its path to market. The long-term implication is a strengthened pipeline and potential for a first-in-class treatment for FSAD.

$DARE positive Positive Phase 1 data for key pipeline asset
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.